Limited Effectiveness of IL-17 Inhibitors for Anti-TNF-Induced Psoriasis in Hidradenitis Suppurativa: A Multicenter Retrospective Study
Por:
Bascón, L, Lluch-Galcerá, JJ, Mora-Fernández, V, Verdaguer-Faja, J, Haselgruber, S, Molina-Leyva, A, Sin-Soler, M, Garbayo-Salmons, P, Mercader-Salvans, J, Araya, VL, Fernández-Crehuet, P, Parra-Navarro, L, Martin-Ezquerra, G, Martin-Poch, A, Carrascosa, JM, Sampayo-Cordero, M, Romaní, J and Vidal, AG
Publicada:
14 abr 2026
Ahead of Print:
1 abr 2026
Resumen:
Background Paradoxical psoriasis (PP) is a known adverse event of anti-tumor necrosis factor (anti-TNF) agents in hidradenitis suppurativa (HS), yet evidence regarding its management remains limited. The objective was to assess the effectiveness of interleukin-17 inhibitors (IL-17i) in treating anti-TNF-induced PP in patients with HS. Methods This multicenter retrospective study included 40 adults with HS who developed PP during anti-TNF therapy and were subsequently treated with IL-17i. Outcomes for PP were measured using the Physician's Global Assessment (PGA); HS severity was evaluated using the International Hidradenitis Suppurativa Severity Score System (IHS4) and Hurley scores. Paired comparisons were performed using the Wilcoxon signed-rank or McNemar's test, as appropriate. Multivariate analysis was performed using LASSO-regularized logistic regression. Missing data were managed by multiple imputation. Results Of the patients, 27.5% achieved a clinically meaningful PP response, while 45% experienced worsening. Female sex, older age at HS onset, and prior exposure to secukinumab were associated with nonresponse. Conversely, HS severity improved significantly in 70% of patients (p < 0.001). Conclusions IL-17i showed limited effectiveness for anti-TNF-induced PP in HS, though improvement in hidradenitis was observed.
Filiaciones:
Bascón, L:
Hosp Gen Granollers, Dept Dermatol, Barcelona, Spain
Lluch-Galcerá, JJ:
Hosp Gen Granollers, Dept Dermatol, Barcelona, Spain
Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
Mora-Fernández, V:
Hosp Univ Germans Trias i Pujol, Dept Dermatol, IGTP, Barcelona, Spain
Verdaguer-Faja, J:
Hosp Univ Germans Trias i Pujol, Dept Dermatol, IGTP, Barcelona, Spain
Haselgruber, S:
Hosp Univ Virgen de Las Nieves Ibs, Granada, Spain
Univ Granada, Dept Dermatol, Ibs, Granada, Spain
Molina-Leyva, A:
Hosp Univ Virgen de Las Nieves Ibs, Granada, Spain
Univ Granada, Dept Dermatol, Ibs, Granada, Spain
Sin-Soler, M:
Hosp Univ Parc Tauli, Dept Dermatol, Barcelona, Spain
Garbayo-Salmons, P:
Hosp Univ Parc Tauli, Dept Dermatol, Barcelona, Spain
Mercader-Salvans, J:
Hosp Univ Canarias, Dept Dermatol, Tenerife, Spain
Araya, VL:
Hosp Univ Canarias, Dept Dermatol, Tenerife, Spain
Fernández-Crehuet, P:
Hosp Univ Reina Sofia, Dept Dermatol, Cordoba, Spain
Maimonides Inst Biomed Res Cordoba IMIB, Cordoba, Spain
Parra-Navarro, L:
Hosp del Mar, Dept Dermatol, Parc Salut del Mar, Barcelona, Spain
Martin-Ezquerra, G:
Hosp del Mar, Dept Dermatol, Parc Salut del Mar, Barcelona, Spain
Martin-Poch, A:
Hosp Univ Sagrat Cor, Dept Dermatol, Grp Quironsalud, Barcelona, Spain
:
Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
Hosp Univ Germans Trias i Pujol, Dept Dermatol, IGTP, Barcelona, Spain
Sampayo-Cordero, M:
Hosp Gen Granollers, Dept Res & Innovat, Granollers, Spain
Romaní, J:
Hosp Gen Granollers, Dept Dermatol, Barcelona, Spain
Vidal, AG:
Hosp Gen Granollers, Dept Dermatol, Barcelona, Spain
Univ Int Catalunya, Barcelona, Spain
|